Aerie Pharmaceuticals Inc (AERI) : Deerfield Management Co reduced its stake in Aerie Pharmaceuticals Inc by 4.25% during the most recent quarter end. The investment management company now holds a total of 2,520,585 shares of Aerie Pharmaceuticals Inc which is valued at $46,454,382 after selling 111,897 shares in Aerie Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Aerie Pharmaceuticals Inc makes up approximately 2.03% of Deerfield Management Co’s portfolio.
Other Hedge Funds, Including , Spark Investment Management sold out all of its stake in AERI during the most recent quarter. The investment firm sold 161,900 shares of AERI which is valued $2,983,817.Tiaa Cref Investment Management boosted its stake in AERI in the latest quarter, The investment management firm added 747 additional shares and now holds a total of 102,456 shares of Aerie Pharmaceuticals Inc which is valued at $1,888,264.Alliancebernstein boosted its stake in AERI in the latest quarter, The investment management firm added 71,201 additional shares and now holds a total of 622,839 shares of Aerie Pharmaceuticals Inc which is valued at $11,478,923. Aerie Pharmaceuticals Inc makes up approx 0.01% of Alliancebernstein’s portfolio.Jennison Associates boosted its stake in AERI in the latest quarter, The investment management firm added 21,505 additional shares and now holds a total of 3,711,695 shares of Aerie Pharmaceuticals Inc which is valued at $66,921,861. Aerie Pharmaceuticals Inc makes up approx 0.07% of Jennison Associates’s portfolio.
Aerie Pharmaceuticals Inc closed down -0.15 points or -0.77% at $19.21 with 2,92,187 shares getting traded on Thursday. Post opening the session at $19.38, the shares hit an intraday low of $18.84 and an intraday high of $19.53 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
Many Wall Street Analysts have commented on Aerie Pharmaceuticals Inc. Cantor Fitzgerald Resumed Aerie Pharmaceuticals Inc on Jun 3, 2016 to “Buy”, Price Target of the shares are set at $44.
Aerie Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates triple-action Rhopressa and quadruple-action Roclatan are once-daily eye drops. The Company’s product candidate once-daily quadruple-action Roclatan is a single drop fixed-dose combination of Rhopressa and latanoprost. Rhopressa inhibits Rho Kinase (ROCK) and the norepinephrine transporter (NET) which are both biochemical targets for lowering intraocular pressure (IOP). The Company’s Rhopressa product candidate was in Phase III stage of development. The Company has completed the Roclatan Phase IIb clinical trial. The Company is also in the preclinical development stage with AR-13533 its second-generation ROCK/NET inhibitor.